logo
Prediction: This Unstoppable "Magnificent Seven" Member Will Be Wall Street's First $5 Trillion Stock, and Billionaire Bill Ackman Just Bought the Dip

Prediction: This Unstoppable "Magnificent Seven" Member Will Be Wall Street's First $5 Trillion Stock, and Billionaire Bill Ackman Just Bought the Dip

Yahoo6 hours ago

Amazon has witnessed a nearly threefold rise in valuation over the last few years, as AI has become more of a central part of the company.
Amazon continues to invest in various areas of AI that can help accelerate revenue growth and profit margin expansion in the long run.
While Amazon stock has recovered from a notable dip last month, it still looks like an attractive buy for long-term investors.
10 stocks we like better than Amazon ›
While there isn't an official start date marking the artificial intelligence (AI) revolution, I personally like to use Nov. 30, 2022, as my timestamp. This is the day that OpenAI released ChatGPT to the public, virtually changing how businesses and consumers access information at the flip of a switch.
Back then, Amazon (NASDAQ: AMZN) sported a market capitalization of $835 billion. Today, the company's value is almost triple -- hovering at around $2.3 trillion.
While Amazon may not fetch as much attention as its "Magnificent Seven" peers Nvidia or Tesla, the company is quietly building a thriving AI ecosystem -- and Wall Street is finally starting to take notice. Last month, investors learned that billionaire hedge fund manager Bill Ackman initiated a stake in Amazon through his investment firm, Pershing Square Capital Management.
Let's explore how Amazon is integrating AI across its various businesses. More importantly, I'll analyze the recent price action in the stock to help make the case for why I think Amazon is positioned to become Wall Street's first $5 trillion stock.
The most obvious area of Amazon's ecosystem that has benefited from the AI boom so far is the company's cloud computing segment, Amazon Web Services (AWS). Over the last couple of years, AWS has invested billions into a start-up called Anthropic, which competes with OpenAI. Throughout this partnership, AWS has witnessed notable revenue acceleration combined with significant expansion in operating margins.
This is an important notion to understand, as AWS accounts for the majority of operating profits across the entire Amazon ecosystem. Thanks to a successful partnership with Anthropic so far, Amazon now has even more financial flexibility, which it can parlay into other AI-powered services.
For instance, Amazon is also testing various forms of AI robotics in its fulfillment centers, which could theoretically bring new levels of efficiency and automation to processes previously managed by human labor.
Lastly, Amazon is also developing its own custom chipsets -- dubbed Trainium and Inferentia. In the long run, these could be more opportunities for Amazon to complement its existing hardware business while entering new markets to compete more directly with existing semiconductor designers.
As of this writing (June 11), Amazon's stock has declined by roughly 1% on the year. While that might initially come across as uninspiring, consider how sharply shares have rebounded since bottoming out at around $167 in April.
It's my suspicion that Ackman took advantage of the sell-off last month and bought the dip. I bring this up because, interestingly, Pershing Square's Amazon position was not included in the fund's 13F filing for the first quarter. Rather, Ackman's Amazon position became publicly reported following news of a call he held with his investors.
The chart below benchmarks Amazon's market cap growth relative to several of its Magnificent Seven peers since the release of ChatGPT. I purposely excluded Apple and Tesla from this analysis, as I don't see much in the way of direct competition to Amazon.
There are a couple of notable takeaways from the trends above.
First, Amazon's valuation has risen considerably more than those of both Microsoft and Alphabet over the last couple of years. This is significant because both companies compete fiercely with Amazon in the cloud computing market, specifically. I see this as a potential signal that investors may be more bullish on Amazon's ability to maintain an edge in the cloud landscape, despite intensifying investments in AI infrastructure from the competition.
In addition, it's clear that Nvidia has been the best Magnificent Seven investment throughout the AI revolution thus far. But as I alluded to above, Amazon actually has a unique opportunity to begin competing with Nvidia through the introduction of its new chipsets.
In my eyes, Amazon has a strong foundation to continue accelerating revenue and profit growth for the long run. Despite already achieving a monster run over the last couple of years, I think investors will continue to place a premium on Amazon stock relative to its peers, leading to further valuation expansion in the years to come.
For these reasons, I believe Amazon's current trajectory supports the idea that the company could see a more than twofold rise in market cap and reach a $5 trillion valuation before its peers.
Before you buy stock in Amazon, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!*
Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Prediction: This Unstoppable "Magnificent Seven" Member Will Be Wall Street's First $5 Trillion Stock, and Billionaire Bill Ackman Just Bought the Dip was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Legal & General Flags Good Start to 2025, Confirms Targets
Legal & General Flags Good Start to 2025, Confirms Targets

Wall Street Journal

time16 minutes ago

  • Wall Street Journal

Legal & General Flags Good Start to 2025, Confirms Targets

Legal & General LGEN 1.38%increase; green up pointing triangle said it made a good start to the year and is on track to deliver on its midterm targets. The London-listed provider of life insurance, pensions, retirement and investment services is aiming to grow its core operating earnings per share by between 6% and 9% per year in the midterm and confirmed on Tuesday that it expects to hit that guidance for 2025.

Those who invested in Geo Energy Resources (SGX:RE4) five years ago are up 499%
Those who invested in Geo Energy Resources (SGX:RE4) five years ago are up 499%

Yahoo

time19 minutes ago

  • Yahoo

Those who invested in Geo Energy Resources (SGX:RE4) five years ago are up 499%

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But when you pick a company that is really flourishing, you can make more than 100%. One great example is Geo Energy Resources Limited (SGX:RE4) which saw its share price drive 217% higher over five years. It's also good to see the share price up 14% over the last quarter. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. During the last half decade, Geo Energy Resources became profitable. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. It might be well worthwhile taking a look at our free report on Geo Energy Resources' earnings, revenue and cash flow. As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, Geo Energy Resources' TSR for the last 5 years was 499%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return. Geo Energy Resources shareholders have received returns of 24% over twelve months (even including dividends), which isn't far from the general market return. We should note here that the five-year TSR is more impressive, at 43% per year. Although the share price growth has slowed, the longer term story points to a business well worth watching. Investors who like to make money usually check up on insider purchases, such as the price paid, and total amount bought. You can find out about the insider purchases of Geo Energy Resources by clicking this link. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Singaporean exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30
SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30

Yahoo

time19 minutes ago

  • Yahoo

SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30

STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed a collaboration and license agreement with Castle Biosciences (NASDAQ: CSTL), a US-based leader in molecular diagnostics. The initial goal of the collaboration is to develop a test that predicts flares in patients diagnosed with atopic dermatitis (AD). The method will be based on SciBase's EIS technology and specifically, Nevisense, inclusive of both the desktop and point-of care devices. In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million, of which Castle Biosciences has undertaken to subscribe for shares corresponding to a total amount of approximately SEK 19 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release. Under the collaboration and license agreement, the Companies will jointly explore and develop various clinical indications related to dermatologic diseases. SciBase's initial territory will be the EU, Switzerland, United Arab Emirates, Japan and South Korea, while Castle Biosciences' initial territory will be North America. Assuming development success, SciBase will receive a single-digit royalty percentage on the Castle gross margin as well as a low double-digit percentage mark-up on product sales to Castle. SciBase will also receive a milestone payment of 5 million U.S. dollars when Castle sales reach 50 million U.S. dollars annually. While the development agreement calls for sharing of development costs, SciBase will be deferring its clinical development costs for the initial indication of pre-symptomatically predicting flares in patients diagnosed with atopic dermatitis, with reimbursement being made from future royalty and milestone payments. "This collaboration with Castle Biosciences is exciting for SciBase," said Pia Renaudin, CEO of SciBase. "It will accelerate the use of Nevisense within the skin barrier health market. It will rapidly broaden our already existing clinical studies pipeline by increasing the number of studies, ultimately speeding up access to more effective therapies for patients with skin barrier dysfunction. We are also pleased to welcome Castle as a shareholder in SciBase." "We are excited to expand our commitment to the dermatologic community, clinicians and patients alike, with the signing of this agreement," said Derek Maetzold, CEO of Castle Biosciences. "Atopic dermatitis is a disease that impacts a significant number of lives, worldwide. We are excited about this opportunity to work with SciBase to develop a test that could improve the management of patients diagnosed with this disease, and potentially other dermatologic diseases. We believe this is a good fit for us, with our existing commercial portfolio of tests in skin cancers, as well as our pipeline test in development for use in patients diagnosed with moderate-to-severe AD who are seeking systemic treatment - the majority of which are managed by the same dermatological clinician." In connection with the collaboration and license agreement, SciBase intends to carry out a directed share issue of approximately SEK 30 million. The subscription price in the directed share issue corresponds to SEK 0.40 per share. Castle Biosciences has undertaken to subscribe for 47,886,950 shares in the directed share issue, corresponding to approximately SEK 19 million. Through the directed share issue, Castle Biosciences is becoming one of SciBase's largest shareholders. Additional information regarding the directed share issue will be announced through a separate press release in connection with this press release and will be available at: About Skin Barrier Dysfunction Skin barrier dysfunction is a key contributing factor to a wide range of skin disorders - including atopic dermatitis, psoriasis, ichthyosis, rosacea, and even acne. Estimates suggest that over 500 million people globally are affected by conditions in which skin barrier impairment plays a central role. Estimated global prevalence by condition includes: Atopic dermatitis (eczema): ~223 million1) Psoriasis: ~125 million2) Rosacea: ~400 million (many with impaired barrier function)3) Additionally, a wide range of cosmetic and subclinical skin concerns-such as dryness, irritation, and product sensitivity-are linked to mild or temporary skin barrier disruption. These milder forms may affect over a billion people globally at some point in their lives. This information is information that SciBase Holding AB is obliged to make public pursuantto the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 22.30 CEST on June 16, 2025. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. For further information please contact: Pia Renaudin, CEO,Phone. +46732069802E-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ)Tel: +46 (0)73 856 42 65E-mail: certifiedadviser@ About SciBase and NevisenseSciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at For press releases and financial reports visit: -------------------------------------------------------------------------------------- 1Global Report on Atopic Dermatitis - 2https:// 3https:// This information was brought to you by Cision The following files are available for download: SciBase PR - collaboration - final Nevisense Go Nevisense new software 2025 with curve EU View original content:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store